Stockchase Opinions

Hugh Cleland, CFA Resverlogix Corp. RVX-T DON'T BUY Mar 26, 2007

Strong management. Have an interesting approach to HDL. Currently pre-clinical, so doesn't know if it works in humans or is safe.
$16.900

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

DON'T BUY
Treatment of Cardiovascular diseases. They’re on to a new way of looking at HDL treatment. Still pre-clinical. Prefers biotech that is at least in phase 2 trials. Too expensive.
COMMENT
Have some compounds that are expected to boost HDL levels significantly. He usually has trouble with pure biotechs, which this one is. They consume vast amounts of cash. Prefers Neptune (NTB-X).
COMMENT
Only process that can reverse a cholesterol situation. A lot of big pharmas are looking at the name. Looks pretty attractive at this level. This is at phase 2 and he prefers buying after phase 3.
COMMENT
(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.